Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $26.00

Astria Therapeutics (NASDAQ:ATXS) had its price target upped by JMP Securities from $25.00 to $26.00 in a research note issued to investors on Wednesday morning,Benzinga reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock.

A number of other equities research analysts have also recently commented on ATXS. Citigroup reaffirmed an “outperform” rating on shares of Astria Therapeutics in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $47.00 price objective on shares of Astria Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Wednesday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and a consensus target price of $29.00.

Astria Therapeutics Stock Up 1.3%

Shares of ATXS opened at $6.85 on Wednesday. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92. The firm has a market capitalization of $386.61 million, a PE ratio of -3.41 and a beta of 0.48. The stock’s fifty day simple moving average is $6.23 and its 200-day simple moving average is $5.76.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.04. Analysts anticipate that Astria Therapeutics will post -1.65 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its stake in Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 2,766 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,557 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in Astria Therapeutics in the 4th quarter valued at approximately $50,000. Virtus ETF Advisers LLC bought a new stake in Astria Therapeutics in the 4th quarter valued at approximately $65,000. Finally, GAMMA Investing LLC lifted its stake in Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 7,971 shares in the last quarter. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.